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In hospital nebulisers are often used in sur-of patients that the power was too low to detect any significant difference between treatgical as well as medical wards and therefore representative personnel from all wards and ments.
10 11 The other three studies investigated more patients and had adequate power to despecialities should be trained to ensure that the bronchodilator is given correctly. In primary tect clinically useful differences. The first from Sweden in 176 patients demonstrated that care nurses and doctors must have appropriate training in nebuliser therapy.
nebulised treatment with a agonist (two doses of salbutamol 0.15 mg/kg 30 minutes apart) At the present time bronchodilators are usually given by nebuliser in acute asthma. In was superior to a bolus injection of 5 g/kg. 12 The second, in 71 severely ill patients not chronic asthma nebulisers are used less frequently, the bronchodilator mostly being de-responding to nebulised treatment, showed that an intravenous infusion of agonist (12.5 g/ livered by metered dose inhaler or dry powder device.
kg) produced significantly more bronchodilatation than repeated administration of nebulised salbutamol over a period of 24 hours (three doses of 5 mg given 30 minutes apart).
13
Acute severe asthma The third study investigated the two treatments Oxygen, corticosteroids, and bronchodilators in severe acute asthma in patients with a peak are widely used in acute asthma (fig 1) . Cortico-flow of less than 150 l/min and found that steroids, however, take several hours to work nebulised treatment produced a greater inand during this time fast acting bronchodilators crease in peak flow and was considered to be can be lifesaving. When bronchospasm is clinically superior. 14 severe, bronchodilators must be given in large Infused agonists may or may not therefore doses and a convenient method of achieving have a useful role in producing bronchothis is by simple nebulisation. dilatation in the small group of asthmatic patients who do not respond to nebulised treatment and further large studies are required.
 
Indications and advantages Dosage Because of severe bronchospasm it was thought No controlled study has been carried out to that bronchodilators given intravenously would determine the dose of agonist to nebulise in be more effective in acute severe asthma. Initial acute asthma and practice therefore varies with studies reported varying results due to the small doses ranging from 2.5 mg to 10 mg. Small numbers of patients producing a result with doses are used in less severe asthma and it low power to detect differences between treatcannot be assumed that such doses will be ments. 2 Comparisons between nebulised adequate in severe asthma. Single doses of 5 mg agonists and intravenous aminophylline have salbutamol by simple nebulisation may produce shown that nebulised agonists produce more only slight relief of airflow obstruction in acute bronchodilatation than aminophylline alone. [3] [4] [5] asthma.
15 A response to a nebulised agonist A meta-analysis of trials investigating the adshould be apparent within 10-15 minutes of dition of aminophylline to nebulised agonists inhaling the drug, and if this is not the case also failed to demonstrate significant additional further doses should be given until an adequate bronchodilatation. 2 3 5-8 Most of these studies, response is produced. This policy usually rehowever, investigated only the early effects of lieves symptoms but, if it fails, other therapeutic intravenous aminophylline. In a recent study measures such as intravenous therapy or asnebulised salbutamol and intravenous aminosisted ventilation should be considered. phylline were compared with nebulised salbutamol alone over 24 hours in 21 patients and a greater percentage improvement in peak flow was reported after a few hours in those Side effects There is therefore no conclusive evidence to severe asthma is very safe but the large doses 
GOOD RESPONSE POOR RESPONSE POOR RESPONSE
Repeat nebulised treatments 4-6 hourly until PEF >75% predicted normal or best and PEF diurnal variability < 25%
Change over to discharge medication by hand-held reliever/preventer 24 hours prior to discharge This flow chart should be used in conjunction with published asthma guidelines.
OR or
Nebulised ␤ agonist + ipratropium bromide (500 µg) Figure 1 Flow chart for management of acute severe asthma in adults.
agonists are, however, very rare. The evidence as a nebulised agonist alone. 18 Early studies with combined ipratropium bromide and that nebulised agonists may aggravate hypagonist were performed in small numbers of oxaemia is not convincing and recent studies patients but most reported more bronchosuggest that the treatment does not produce any dilatation than with agonist alone. In two significant falls in arterial oxygen saturation.
15 17 large studies on 56 and 148 patients with acute No deterioration in hypoxaemia was recorded asthma significant differences between the in 32 hypoxaemic patients admitted with acute treatments were recorded with the combination severe asthma to whom nebulised salbutamol producing significantly greater bronchowas given in doses ranging from 1.5 mg to dilatation in the first four hours of treatment 5 mg using an air compressor. 15 In domiciliary than that following a agonist alone, 18 19 parpractice lack of oxygen to drive a nebuliser ticularly in those with very severe asthma should not preclude giving agonist.
(forced expiratory volume in one second (FEV 1 ) <1.0 litre or peak expiratory flow <140 l/min) in whom the mean FEV 1 improved    by 55.6% with the combined treatment and Indications and advantages 38.9% with the agonist alone. In acute severe asthma nebulised ipratropium A meta-analysis of the use of a nebulised bromide alone is not as good a bronchodilator agonist and ipratropium bromide in acute group.bmj.com on August 15, 2017 -Published by http://thorax.bmj.com/ Downloaded from asthma has suggested that, on average, ipra-  Conflicting reports indicate that further areas tropium produces a mean increase in the peak expiratory flow rate of 44 l/min (95% con-for research in acute asthma include the possible use of spacing devices attached to metered fidence interval 17 to 61) more than that produced by agonist alone. 20 These have been dose inhalers instead of nebulisers. 28-30 Also, there have been few investigations to determine short term studies and therefore the optimum duration of this combined treatment is not the best treatment for those asthmatic patients who do not respond to initial treatment with known.
nebulised agonists. Many studies have been conducted in emergency departments and have only investigated treatments for up to two or four hours. Further research is required to Dosage determine the best ways of treating acute A cumulative dose response study in only six asthma during the first 24-48 hours after adpatients suggested that 0.5 mg nebulised ipra-mission and ways of preventing readmission tropium produced a maximum bronchodilator with further acute attacks. The role of nebulised response in patients with acute severe asthma. 21 corticosteroid in acute asthma will no doubt Following this small study an investigation be investigated. comparing 0.5 mg with 1.0 mg nebulised ipratropium in acute asthma found no difference in the mean rise in peak flow between the Chronic asthma and brittle asthma treatments, 22 and this has led to the re-Nebulised bronchodilators may be given to commended dose of 0.5 mg.
relieve symptoms in patients with chronic persistent wheeze or to those with sudden catastrophic severe (brittle) asthma. The use of nebulisers without proper assessment and supervision is potentially dangerous.
Side effects
Some patients with severe chronic airflow Prolonged pupillary dilatation and loss of acobstruction who remain symptomatic despite commodation can occur if ipratropium is treatment with inhaled reliever and high dose sprayed directly into the eye. This complication inhaled preventer derive benefit from inhaling can lead to acute glaucoma in adults and may a bronchodilator in a large dose. 31 Historically happen if nebuliser solutions are given with a this has been done by nebuliser. In many cases, face mask rather than a mouthpiece. Similar however, this may not be necessary as 4-6 puffs adverse reactions are not likely in children. 23 It of a metered dose inhaler fitted with a spacer is unusual for nebulised ipratropium to cause device with tidal breathing produces the same urinary problems, but when high doses are result.
29 30
repeatedly nebulised in susceptible individuals In some patients, however, a nebuliser is this may precipitate urinary retention. Nebustill considered and then it is important that lised ipratropium has no detrimental effect on guidelines for the treatment of chronic asthma arterial hypoxaemia and does not affect cardiac are followed. 26 27 Such guidelines include advice rate. 22 before prescribing the nebuliser: Paradoxical bronchoconstriction has been (1) Is the diagnosis correct? Is the airway obreported, but very rarely. At first this was struction significantly reversible? thought to be due to the hypotonicity of the (2) Has the inhaler technique been checked nebuliser solution, 24 and then to preservatives and has a large volume spacer been tried? in the solution. 25 Nebuliser solutions are now (3) Has a large dose of bronchodilator via a isotonic and preservative free but the problem spacer device been used? may still arise and the treatment should be (4) Is the patient complying with regular antiwithdrawn if the patient does not respond in inflammatory therapy? the expected manner. Paradoxical broncho-(5) An initial home trial should be undertaken constriction can occur with any nebulised drug.
to determine if worthwhile bronchodilatation is obtainable. An increase in bronchodilatation without unacceptable side effects should be demonstrated, preferably with a home trial for at least two         weeks with monitoring of peak flow. Not every patient will benefit from high dose nebulised Patients should not be discharged from hospital until their medication has been changed to that treatment and an increase in mean baseline peak flow of 15% or more should be demwhich they will be taking at home. This change should then be monitored for 24 hours to onstrated. Peak flow should be measured for two weeks on standard treatment and then for ensure that the asthma does not deteriorate once the nebuliser treatment has been stopped. two weeks on nebulised treatment. Peak flow measurements should be taken twice daily beThe change over should not take place until the peak expiratory flow rate (PEFR) is at least fore nebulisation on rising and going to bed.
In addition, a peak flow measurement should 75% of the predicted value or of the best level and a diurnal variability of less than be taken 30 minutes after treatment in the morning. 25% (diurnal variability=highest PEFR -lowest PEFR/highest PEFR×100 in each 24
A few asthmatic patients develop sudden severe asthma attacks within minutes or a few hours).
